Woodsmoke Particulate + Prednisone

Summary

Woodsmoke Particulate + Prednisone is a clinical trial^[1].

Key Facts

• Woodsmoke Particulate + Prednisone is in the country of United States^[2].
• Woodsmoke Particulate + Prednisone's instance of is recorded as clinical trial^[3].
• Woodsmoke Particulate + Prednisone's start time is recorded as +2019-03-22T00:00:00Z^[4].
• Woodsmoke Particulate + Prednisone's end time is recorded as +2022-02-28T00:00:00Z^[5].
• Woodsmoke Particulate + Prednisone's sponsor is recorded as University of North Carolina at Chapel Hill^[6].
• Woodsmoke Particulate + Prednisone's main subject is recorded as inflammation^[7].
• Woodsmoke Particulate + Prednisone's number of participants is recorded as {'unit': '1', 'amount': '+24'}^[8].
• Woodsmoke Particulate + Prednisone's title is recorded as Phase I/II Randomized, Double-blind, Placebo-controlled Cross-over Study of Prednisone on Airway Inflammatory Response to Inhaled Wood Smoke.^[9].
• Woodsmoke Particulate + Prednisone's short name is recorded as Smokisone^[10].
• Woodsmoke Particulate + Prednisone's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Woodsmoke Particulate + Prednisone's ClinicalTrials.gov ID is recorded as NCT03861390^[12].
• Woodsmoke Particulate + Prednisone's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}^[13].
• Woodsmoke Particulate + Prednisone's research intervention is recorded as prednisone^[14].
• Woodsmoke Particulate + Prednisone's clinical trial phase is recorded as phase I clinical trial^[15].
• Woodsmoke Particulate + Prednisone's clinical trial phase is recorded as phase II clinical trial^[16].
• Woodsmoke Particulate + Prednisone's study type is recorded as interventional study^[17].